Table 1.
Variables |
PCSK9 below median (<1.94 U/mL) (n = 20) |
PCSK9 above median (>1.94 U/mL) (n = 20) |
P |
---|---|---|---|
Demographics and medical history | |||
Age (years) | 59 ± 12 | 60 ± 12 | 0.638 |
Male, n (%) | 17 (85) | 16 (80) | 0.677 |
Hypertension, n (%) | 12 (60) | 10 (50) | 0.525 |
Diabetes mellitus, n (%) | 4 (20) | 4 (20) | 1 |
Dyslipidemia, n (%) | 4 (20) | 11 (55) | 0.022 |
Smoker, n (%) | 13 (65) | 11 (55) | 0.519 |
Anterior infarction, n (%) | 15 (75) | 12 (60) | 0.311 |
GRACE score | 137 ± 28 | 147 ± 38 | 0.321 |
TIMI risk scorea | 3 (1.5–4) | 2 (1.5–3.5) | 0.499 |
Laboratory data | |||
Killip class ≥ II, n (%) | 6 (30) | 3 (15) | 0.256 |
Peak hsTnT (ng/mL)a | 3631 (1772–4987) | 3702 (2892–7627) | 0.159 |
ST2 (pg/mL)a | 86.7 (37.9–113.8) | 103.9 (63.2–135.9) | 0.083 |
PCSK9 (U/mL) | 1.64 ± 0.25 | 2.22 ± 0.23 | <0.001 |
CMR at 1 week | |||
LVEF (%) | 42 ± 7 | 41 ± 7 | 0.641 |
LVEDVI (mL/m2) | 84 ± 18 | 78 ± 20 | 0.445 |
LVESVI (mL/m2) | 48 ± 11 | 48 ± 17 | 0.953 |
Infarct size (%)a | 28 (19–34) | 30 (26–41) | 0.206 |
MVO (%) | 2.1 ± 0.4 | 2.6 ± 0.6 | 0.482 |
Medical treatment at discharge | |||
Aldosterone receptor blockers, n (%) | 8 (40) | 4 (20) | 0.168 |
ACEI/ARB, n (%) | 13 (65) | 18 (90) | 0.058 |
Beta blockers, n (%) | 13 (65) | 13 (65) | 1 |
Statins, n (%) | 13 (65) | 19 (95) | 0.018 |
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; CMR, cardiac magnetic resonance; GRACE, Global Registry of Acute Coronary Events; hsTnT, high‐sensibility troponin T; LVEDVI, left ventricular end‐diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end‐systolic volume index; MVO, microvascular obstruction; PCSK9, proprotein convertase subtilisin/kexin type 9; ST2, soluble interleukin‐1 receptor‐like 1; TIMI, Thrombolysis in Myocardial Infarction.
Values for continuous variables are expressed as mean ± SD unless otherwise specified.
Values expressed as median (interquartile range).